Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia

MeSH terms

• Aged
• Alemtuzumab
• Anemia, Hemolytic, Autoimmune / drug therapy*
• Anemia, Hemolytic, Autoimmune / etiology
• Antibodies, Monoclonal / administration & dosage*
• Antibodies, Monoclonal / adverse effects
• Antibodies, Monoclonal, Humanized
• Antibodies, Neoplasm / administration & dosage*
• Antibodies, Neoplasm / adverse effects
• Antineoplastic Agents / administration & dosage*
• Antineoplastic Agents / adverse effects
• Hemoglobins / analysis
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell / complications*
• Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
• Leukemia, Lymphocytic, Chronic, B-Cell / immunology
• Male
• Middle Aged
• Treatment Outcome